20 July 2023 
EMA/245419/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Tyenne 
tocilizumab 
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Tyenne, 
intended for the treatment of rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (sJIA), 
juvenile idiopathic polyarthritis (pJIA), giant cell arteritis (GCA), CAR-T cell-induced severe or life-
threatening CRS and coronavirus disease 2019 (COVID-19)  
The applicant for this medicinal product is Fresenius Kabi Deutschland GmbH. 
Tyenne will be available as a 20 mg/ml concentrate for solution for infusion and a 162 mg/mL solution for 
injection. The active substance of Tyenne is tocilizumab, an interleukin inhibitor (ATC code: L04AC07). 
Tocilizumab is a recombinant humanised anti-human interleukin-6 receptor (IL-6R) monoclonal antibody 
of the immunoglobulin IgG1 subclass inhibiting soluble and membrane-bound interleukin-6 receptors 
implicated in the pathogenesis of different diseases, including inflammatory diseases. 
Tyenne is a biosimilar medicinal product. It is highly similar to the reference product RoActemra 
(tocilizumab), which was authorised in the EU on 16 January 2009. Data show that Tyenne has 
comparable quality, safety and efficacy to RoActemra. More information on biosimilar medicines can be 
found here. 
The full indication is: 
Tyenne 20 mg/mL concentrate for solution for infusion 
Tyenne, in combination with methotrexate (MTX), is indicated for: 
• 
the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not 
previously treated with MTX. 
• 
the treatment of moderate to severe active RA in adult patients who have either 
responded inadequately to, or who were intolerant to, previous therapy with one or more 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) 
antagonists. 
In these patients, Tyenne can be given as monotherapy in case of intolerance to MTX or where 
continued treatment with MTX is inappropriate. 
Tocilizumab been shown to reduce the rate of progression of joint damage as measured by X-
ray and to improve physical function when given in combination with methotrexate. 
Tyenne is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are 
receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. 
Tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in 
patients 2 years of age and older, who have responded inadequately to previous therapy with 
NSAIDs and systemic corticosteroids. Tyenne can be given as monotherapy (in case of 
intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX. 
Tyenne in combination with methotrexate (MTX) is indicated for the treatment of juvenile 
idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) 
in patients 2 years of age and older, who have responded inadequately to previous therapy with 
MTX. Tyenne can be given as monotherapy in case of intolerance to MTX or where continued 
treatment with MTX is inappropriate. 
Tyenne is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced 
severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 
2 years of age and older. 
Tyenne 162 mg solution for injection in pre-filled syringe 
Tyenne, in combination with methotrexate (MTX), is indicated for: 
• 
the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not 
previously treated with MTX. 
• 
the treatment of moderate to severe active RA in adult patients who have either responded 
inadequately to, or who were intolerant to, previous therapy with one or more disease-
modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. 
In these patients, Tyenne can be given as monotherapy in case of intolerance to MTX or where 
continued treatment with MTX is inappropriate. 
Tocilizumab has been shown to reduce the rate of progression of joint damage as measured by 
X-ray and to improve physical function when given in combination with methotrexate. 
Tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in 
patients 1 year of age and older, who have responded inadequately to previous therapy with 
NSAIDs and systemic corticosteroids. Tyenne can be given as monotherapy (in case of 
intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX. 
Tyenne  
EMA/245419/2023 
Page 2/4 
 
 
 
 
 
 
 
 
 
Tyenne in combination with methotrexate (MTX) is indicated for the treatment of juvenile 
idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) 
in patients 2 years of age and older, who have responded inadequately to previous therapy with 
MTX.  
Tyenne can be given as monotherapy in case of intolerance to MTX or where continued 
treatment with MTX is inappropriate. 
Tyenne is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients. 
Tyenne 162 mg solution for injection in pre-filled pen 
Tyenne, in combination with methotrexate (MTX), is indicated for 
• 
the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not 
previously treated with MTX. 
• 
the treatment of moderate to severe active RA in adult patients who have either 
responded inadequately to, or who were intolerant to, previous therapy with one or more 
disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) 
antagonists. 
In these patients, Tyenne can be given as monotherapy in case of intolerance to MTX or where 
continued treatment with MTX is inappropriate. 
Tocilizumab has been shown to reduce the rate of progression of joint damage as measured by 
X-ray and to improve physical function when given in combination with methotrexate. 
Tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in 
patients 12 years of age and older, who have responded inadequately to previous therapy with 
NSAIDs and systemic corticosteroids (see Section 4.2). Tyenne can be given as monotherapy (in 
case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with 
MTX. 
Tyenne in combination with methotrexate (MTX) is indicated for the treatment of juvenile 
idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) 
in patients 12 years of age and older, who have responded inadequately to previous therapy 
with MTX (see Section 4.2). 
Tyenne can be given as monotherapy in case of intolerance to MTX or where continued 
treatment with MTX is inappropriate. 
Tyenne is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.” 
Treatment should be initiated by healthcare professionals experienced in the diagnosis and treatment of 
RA, COVID-19, sJIA, pJIA, CRS, and/or GCA. All patients treated with Tyenne should be given the Patient 
Alert Card. 
Detailed recommendations for the use of this product will be described in the summary of product 
Tyenne  
EMA/245419/2023 
Page 3/4 
 
 
 
 
 
 
 
 
 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
Tyenne  
EMA/245419/2023 
Page 4/4 
 
 
 
 
